- William G. Kachioff appointed as Chief Financial Officer
- James A. Vollins appointed as
General Counsel, Chief Compliance Officer and Corporate
Secretary
PALO
ALTO, Calif., April 13,
2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
(Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused
on the development of innovative therapies for hepatitis delta
virus (HDV) and other serious diseases, today announced the
appointments of William G. Kachioff as Chief Financial Officer, and
James A. Vollins as General Counsel,
Chief Compliance Officer and Corporate Secretary.
"We are excited to welcome two seasoned biotech executives to
the Eiger executive team, both of whom have a proven track record
of delivering results and creating significant shareholder value,"
said David Apelian, MD, PhD, Interim
CEO, Eiger. "Mr. Kachioff brings extensive financial and strategic
expertise, combined with a deep knowledge of the biotechnology
sector. Mr. Vollins' extensive legal expertise and insight will be
invaluable as we continue to advance our programs. Their
appointments come during a pivotal time as we complete our program
prioritization analyses to assess the most promising drivers of
shareholder value. Both will be strong partners as we complete the
transition and lead the company forward."
"I'm thrilled to join Eiger given the company's deep pipeline of
promising innovative agents to treat rare diseases," said Mr.
Kachioff. "This deep pipeline has the potential to provide
tremendous optionality to build shareholder value. I look forward
to contributing to the company's near-term prioritization process
as well as helping the company execute its strategic plan and
deliver value for its shareholders."
"I am honored by the opportunity to lead Eiger's legal and
compliance organization in our mission to develop innovative
therapies for the treatment of serious diseases," said Mr. Vollins.
"I look forward to contributing to the next phase of Eiger's
planned growth with a commitment to integrity and compliance while
increasing shareholder value."
Mr. Kachioff is highly experienced in corporate finance,
investor relations, capital formation, corporate governance and
manufacturing accounting and systems. He has over 30 years of life
sciences industry experience and is currently a consulting CFO with
Danforth Advisors, with whom Eiger has contracted for his services.
He recently served as interim CFO at Aduro Biotech (now Chinook
Therapeutics), a publicly-traded, clinical-stage cancer
immunotherapy company and previously served as CFO at GenomeDx
Biosciences (now Veracyte) and Biocept, two providers of novel
cancer diagnostic services. Prior to that, he was CFO at Althea
Technologies (now Ajinomoto Bio-Pharma), a pharmaceutical contract
manufacturer. Mr. Kachioff has served as CFO at MicroIslet, a
publicly-traded biotech company developing cell transplant
therapies for insulin-dependent diabetes and was Director of
Finance at Cutera, where he prepared the company for the commercial
launch of its first product and its initial public offering. Mr.
Kachioff has a B.S. in management from the State University of New York at Buffalo and is a
member of the American Institute of Certified Public Accountants
and the Association of Bioscience Financial Officers. He began his
professional career as an auditor with Deloitte.
Mr. Vollins is an experienced public company, biotechnology, and
healthcare compliance attorney with significant executive
leadership experience and a focus on scaling high-quality biotech
companies and best-in-class compliance programs. During his 30-year
legal career, he has worked for several global biotechnology
companies in roles of increasing responsibility. Prior to joining
Eiger, Mr. Vollins was General Counsel, Chief Compliance Officer
and Corporate Secretary at BioDelivery Sciences International, Inc.
Prior to that, he was General Counsel, Chief Compliance Officer and
Corporate Secretary at Bio Products Laboratory Limited. Mr. Vollins
also served in a variety of roles with increasing responsibility at
Grifols Inc., Talecris Biotherapeutics, Inc. and Pfizer Inc. Mr.
Vollins' career highlights include several significant M&A
transactions, numerous successful drug launches, and the IPO of
Talecris Biotherapeutics, Inc. He began his legal career as a
commercial litigator and has tried cases and argued appeals in
state and federal courts throughout the U.S.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on
the development of innovative therapies for hepatitis delta virus
(HDV) and other serious rare diseases. The Eiger HDV platform
includes two first-in-class therapies in Phase 3 that target
critical host processes involved in viral replication. All five
Eiger rare disease programs have been granted FDA breakthrough
therapy designation.
For additional information about Eiger and its clinical
programs, please visit www.eigerbio.com.
Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements other than statements
of historical facts, including statements regardingour
ability to advance our programs, our ability to drive
shareholder value, Eiger's program prioritization
analyses, the timing for and outcomes of clinical results, our
business strategy and plans and objectives for future operations,
are forward-looking statements. Forward-looking statements are our
current statements regarding our intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things, the timing of our ongoing and planned clinical development;
the sufficiency of our cash, cash equivalents and investments to
fund our operations; our ability to finance, independently or
through collaborations, the continued advancement of our
development pipeline; and the potential for success of any of our
products or product candidates. Various important factors could
cause actual results or events to differ materially from the
forward-looking statements that Eiger makes, including
additional applicable risks and uncertainties described in the
"Risk Factors" sections in the Annual Report on Form 10-K for the
year ended December 31, 2022
and Eiger's subsequent filings with the SEC. The
forward-looking statements contained in this press release are
based on information currently available to Eiger and
speak only as of the date on which they are made. Eiger
does not undertake and specifically disclaims any obligation
to update any forward-looking statements, whether as a result of
any new information, future events, changed circumstances or
otherwise.
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-strengthens-management-team-with-new-appointments-301796463.html
SOURCE Eiger BioPharmaceuticals, Inc.
